[1] Hochberg J，Waxman IM，Kelly KM，et al. Adolescent non-hodgkin lymphoma and Hodgkin lymphoma：state of the science[J]. Br J Haematol，2009，144(1)：24-40. [2] Bollard CM，Lim MS，Gross TG，et al. Children’s Oncology Group’s 2013 blueprint for research：non-Hodgkin lymphoma[J]. Pediatr Blood Cancer，2013，60(6)：979-984. [3] Abla O，Weitzman S，Blay JY，et al. Primary CNS lymphoma in children and adolescents：a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)[J]. Clin Cancer Res，2011，17(2)：346-352. [4] Patte C，Auperin A，Michon J，et al. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol：highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. [J] Blood，2001，97(11)：3370-3379. [5] Patte C，Auperin A，Gerrard M，et al. Results of the randomized international FAB/LM96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents：it is possible to reduce treatment for the early responding patients[J]. Blood，2007，109(7)：2773-2780. [6] Pillon M，Di Tullio MT，Garaventa A，et al. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92)[J].Cancer，2004，101(2)：385-394. [7] Gerrard M，Cairo MS，Weston C，et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma：results of the FAB/LMB96 international study[J]. Br J Haematol，2008，141(6)：840-847. [8] Woessmann W，Seidemann K，Mann G，et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms：a report of the BFM Group Study NHL-BFM95 [J]. Blood，2005，105(3)：948-968. [9] Fujita N，Kobayashi R，Takimoto T，et al. Results of the Japan Association of Childhood leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hogkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood [J]. Leuk Lymphoma，2011，52(2)：223-229. [10] Reiter A. Non-Hodgkin lymphoma in children and adolescents[J]. Klin Padiatr，2013，225 Supp1：S87-S93. [11] Cairo MS，Gerrard M，Sposto R，et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents [J]. Blood，2007，109(7)：2736-2743. [12] Reiter A. Diagnosis and treatment of childhood non-hodgkin lymphoma [J]. Hematology Am Soc Hematol Educ Program，2007：285-296. [13] Miles RR，Arnold S，Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia [J]. Br J Haematol，2012，156(6)：730-743. [14] Worch J，Rohde M，Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives [J]. Pediatr Hematol Oncol，2013，30(6)：465-483. [15] Poirel HA，Cairo MS，Heerema NA，et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma：results of the FAB/LMB96 international study [J].Leukemia，2009，23(2)：323-331. [16] Nelson M，Perkins SL，Dave BJ，et al. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact in survival in children and adolescents with Burkitt lymphoma：results from the Children’s Oncology Group study CCG-5961 [J]. Br J Haematol，2010，148(4)：600-610. [17] Shiramizu B，Goldman S，Kusao I，et al. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (stage III/IV) B-cell non-Hodgkin lymphoma：a children’s oncology group report [J]. Br J Haematol，2011，153(6)：758-763. [18] Reiter A，Schrappe M，Tiemann M，et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy：a report of the Berlin-Frankfurt-Müster Group Trial NHL-BFM 90 [J]. Blood.1999;49(10)：3294-3306.
